The CCL2 synthesis inhibitor bindarit targets cells of the neurovascular unit, and suppresses experimental autoimmune encephalomyelitis

BACKGROUND: Production of the chemokine CCL2 by cells of the neurovascular unit (NVU) drives critical aspects of neuroinflammation. Suppression of CCL2 therefore holds promise in treating neuroinflammatory disease. Accordingly, we sought to determine if the compound bindarit, which inhibits CCL2 syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Shujun, Shrestha, Bandana, Paul, Debayon, Keating, Carolyn, Cone, Robert, Guglielmotti, Angelo, Pachter, Joel S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488971/
https://www.ncbi.nlm.nih.gov/pubmed/22788993
http://dx.doi.org/10.1186/1742-2094-9-171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488971/
https://www.ncbi.nlm.nih.gov/pubmed/22788993
http://dx.doi.org/10.1186/1742-2094-9-171

Ejemplares similares